New Search

If you are not happy with the results below please do another search

34 search results for: drug interaction cbd

13

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial

/in

Are there acute pharmacokinetic or pharmacodynamic differences between oral ingestion of a Δ9-tetrahydrocannabinol (Δ9-THC)-dominant cannabis extract compared with a cannabidiol (CBD)-dominant extract at the same Δ9-THC dose (20 mg) in healthy adults who use cannabis infrequently? In this randomized clinical trial including 18 adult participants, ingestion of 20 mg Δ9-THC + 640 mg CBD resulted in stronger subjective drug effects, greater impairment of cognitive and psychomotor ability, and greater increase in heart rate relative to 20 mg Δ9-THC alone and placebo. These effects appear to be mediated by CBD inhibition of Δ9-THC and 11-OH-Δ9-THC metabolism.

14

Cannabidiol in refractory status epilepticus: A review of clinical experiences

/in ,

To summarize and evaluate clinical experiences with refractory status epilepticus in which cannabidiol (CBD) was utilized for cessation of seizure activity. A comprehensive literature review was performed on PubMED, MEDLINE, Scopus, and CINAHL between May – June 2022 with the assistance of a medical reference librarian using the following search terms: “Cannabidiol” [MAJR], “Status Epilepticus” [MAJR], “New-Onset Refractory Status Epilepticus”, and “cannabidiol.” Reports that provided dosing regimens and patient outcomes were included.

15

Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients

/in ,

The management of behavioral symptoms and rigidity in patients with dementia constitutes a significant challenge. Short-term studies suggest an interest in the use of medical cannabis, but long-term data are lacking. The objective of this study was to investigate the feasibility and long-term safety of administering tetrahydrocannabinol/cannabidiol (THC/CBD) treatment as an additional drug to a poly medicated population with severe dementia, evaluate clinical improvements, and collect information on the pharmacokinetics of cannabinoids and possible drug–drug interactions.

21

The pharmacokinetics and the pharmacodynamics of cannabinoids

/in

There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regarding their pharmacokinetics and pharmacodynamics to guide prescribers. Cannabis medicines contain a wide variety of chemical compounds, including the cannabinoids delta‐9‐tetrahydrocannabinol (THC), which is psychoactive, and the nonpsychoactive cannabidiol (CBD). Cannabis use is associated with both pathological and behavioural toxicity and, accordingly, is contraindicated in the context of significant psychiatric, cardiovascular, renal or hepatic illness.

22

Using Cannabis in End-of-Life Care

/in ,

Dr. Genevieve Newton explores how cannabis therapeutics may be a beneficial addition to hospice and palliative care. Discover the science and hear from experts in the field.

23

Cannabis, Anxiety & Depression

/in ,

Dr. Genevieve Newton outlines the preclinical and clinical research on the applications of cannabis for anxiety and depression.

24

Safety Considerations in Cannabinoid-Based Medicine

/in

Authors Joshua Aviram, Gil M. Lewitus, Yelena Vysotski, Anton Uribayev, Shiri Procaccia, Idan Cohen, Anca Leibovici, Mahmud Abo-Amna, Luiza Akria, Dmitry Goncharov, Neomi Mativ, Avia Kauffman, Ayelet Shai, Or Hazan,…